Evolus

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evolus, Inc. provides medical aesthetic products and competes against Botox with its main product, Jeuveau. The company is gaining market share and continues to add members to its core loyalty program. Evolus is expected to deliver 30% annual revenue growth in the coming years, and losses should continue to narrow with profitability in sight for 2025.

Evolus: Gaining Market Share

Clean Energy Fuels

DocGo

FREYR Battery SA

NaaS Technology Inc

NerdWallet

SoundHound AI Inc

To be quite blunt, small-cap stocks to buy are like the chimpanzees of the equities space. While you may mistake a chimp for being weak due to its relatively short stature, that would be a mistake.

7 Small-Cap Stocks Analysts Predict Will Double in 2024

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will be participating in two investment conferences in September. Event: H.C. Wainwright 25th Annual Global Investment Conference Date: Tuesday, September 12, 2023 Time: 11:00 – 11:30 am ET Event: Cantor 2023 Global Healthcare Conference Date: Tuesday, September 26, 2023 Time: 9:1.

Evolus to Participate in September Conferences

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 83,555 shares of Evolus common stock and 63,358 restricted stock units (RSUs) to Tomoko Yamagishi-Dressler, the company's new Chief Marketing Officer. The stock options and RSUs were granted as o.

Evolus Announces Inducement Grants for New Chief Marketing Officer

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (CMO), effective today.

Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus unveils fresh, new branding for its flagship neurotoxin product, Jeuveau.

Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers

Evolus, Inc. (NASDAQ:EOLS ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants David Erickson - VP, IR David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research & Development Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Navann Ty - BNP Louise Chen - Cantor Fitzgerald Doug Tsao - H.C. Wainwright Serge Belanger - Needham & Company Operator Greetings and welcome to the Evolus Second Quarter 2023 Earnings Conference Call.

Evolus, Inc. (EOLS) Q2 2023 Earnings Call Transcript

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.38 per share a year ago.

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus reported financial results for the second quarter ended June 30, 2023 and provided a business update.

Evolus Reports Second Quarter 2023 Results and Provides Business Update

The company increased full-year revenue guidance to between $185 million and $195 million. Second-quarter revenue was up 33% year over year.

Why Shares of Evolus Are Jumping Thursday

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus reported revenue for the second quarter ended June 30, 2023 and raised its revenue guidance for the full year.

Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue

Evolus, Inc. (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus announced that members of its management team will be participating in Canaccord Genuity's 43rd Annual Growth Conference in Boston.

Evolus to Participate in Canaccord Genuity's 43rd Annual Growth Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus announced that it will report its second quarter 2023 financial results and provide a business update on Wednesday, August 2, 2023.

Evolus to Report Second Quarter 2023 Results and Provide Business Update

Evolus, Inc., a pharmaceutical company specializing in aesthetic products, faces significant challenges with its lead product Jeuveau, a treatment for frown lines. Jeuveau's undifferentiated clinical data compared to established competitor Botox, aggressive pricing strategies in the market, and the entry of long-acting neurotoxins like Daxxify from Revance make its launch and market penetration difficult. The company's financial position is precarious, with only $31m cash on hand and a quarterly cash burn rate of $15m. The company's value is heavily reliant on Jeuveau, making it vulnerable to market shifts and changes in consumer preference.

Evolus: Botox Copy Cat In A Challenging Aesthetic Market

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. has commenced the commercial launch of Nuceiva® in Italy. The product is now available for direct order and delivery to customers.

Evolus Launches Nuceiva® (botulinum toxin type A) in Italy

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. announced the completion of its Phase 2 clinical study evaluating an “extra-strength” dose for extended duration of Jeuveau®.

Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. announced it recently completed the one-millionth Jeuveau® redemption through its Evolus Rewards™ patient loyalty program.

Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program

Evolus, Inc. (NASDAQ:EOLS ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants David Erickson - VP, IR David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research & Development Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Marc Goodman - SVB Securities Douglas Tsao - H.C. Wainwright Operator Greetings, and welcome to the Evolus First Quarter 2023 Earnings Conference Call.

Evolus, Inc. (EOLS) Q1 2023 Earnings Call Transcript

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.27 per share a year ago.

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus, Inc. reports financial results for the first quarter ended March 31, 2023 and provides a business update.

Evolus Reports First Quarter 2023 Results and Provides Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus, Inc. announces it has entered into a definitive agreement to be the exclusive U.S. distributor of a line of five unique dermal fillers.

Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus, Inc. announces that it will report its first quarter 2023 financial results and provide a business update on Tuesday, May 9, 2023.

Evolus to Report First Quarter 2023 Results and Provide Business Update

Evolus: Capitalizing On The Growth Of Aesthetics Market

Evolus, Inc. (NASDAQ:EOLS ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants David Erickson - Vice President of Investor Relations David Moatazedi - President and Chief Executive Officer Rui Avelar - Chief Medical Officer and Head of Research and Development Sandra Beaver - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel, Nicolaus & Company, Inc. Marc Goodman - SVB Securities Douglas Tsao - H.C. Wainwright & Co. Louise Chen - Cantor Fitzgerald & Co. Navann Ty - BNP Paribas Exane Serge Belanger - Needham & Company, LLC Gregory Fraser - Truist Securities, Inc. Uy Ear - Mizuho Securities Co. Operator Greetings, and welcome to the Evolus Fourth Quarter 2022 Earnings Conference Call.

News for Evolus Stock (EOLS)